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Background: There is evidence in the literature that inhaled corticosteroids (ICSs) are safe
for pregnant women with asthma and their infants. Although this is useful information
about ICS use during pregnancy, some articles must be viewed cautiously because of lack of
power and adjustment for potentially important confounding variables.
Objective: To summarize evidence on the potential effects of ICSs to treat asthma in
pregnant mothers and their children with particular focus on study power.
Methods: Studies published before September 1, 2007, and focusing mainly on ICS use for
asthma treatment during pregnancy were researched in Pubmed and the Cochrane Library.
Post hoc power calculations were completed using data reported in the published articles.
Results: Twenty-three studies that evaluated the associations between ICS use during
pregnancy and maternal and/or perinatal outcomes were retained. Only six studies on the
association between ICS use and maternal outcomes reported significant results; five
studies found significant associations between ICS use and perinatal outcomes. Regarding
non-significant results, two studies on maternal outcomes and seven studies on perinatal
outcomes had a power higher than 80% to detect a relative risk of 1.5 or a mean birth
weight difference of 500 g.
Conclusion: While there currently is some degree of evidence to support the safety of ICS
use during pregnancy, this review highlights the limited statistical power of several studies
published in this area.
& 2008 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Asthma is a common chronic condition, affecting from 4% to
8% of women of childbearing age.1–3 Current asthma
guidelines recommend that pregnant women be treated as
aggressively as they were before the onset of pregnancy,
since uncontrolled asthma is believed to be more harmful to
both the mother and child than the medications used to
control the disease.2 However, many women who become
pregnant worry about their prescribed medications and
wonder if they should comply with their asthma treat-
ments.4,5 This rationale may explain partly the recurrent
observation that tends to demonstrate that a large propor-
tion of women with asthma do not optimally manage their
treatment during pregnancy.6–8
Inhaled corticosteroids (ICSs) are the cornerstone of
asthma treatment and are recommended for use during
pregnancy.1,2,9 The literature provides a certain degree
of evidence relative to the safety of ICSs in pregnant
women and their infants. Most common maternal out-
comes studied in association with the use of ICSs during
pregnancy include pregnancy-induced hypertension
and preeclampsia,10–18 caesarean section,11,13,15–17,19 asth-
ma exacerbations,6,7,14,15,17,20–23 hemorrhage,15–17 and ge-
stational diabetes,13,16,21,22 whereas infant outcomes
often include congenital malformations,10,11,13,14,16–18,20–31
birth weight,10,13,15–19,21–23,27,28,30,32,33 prematur-
ity,10,13–18,21,22,27,30,34 stillbirth,14,15,19,22,27 and neona-
tal15,22,27 and perinatal17 death. Although those studies
provide healthcare professionals with crucial information
related to the use of ICSs for the treatment of asthma in
pregnancy, most articles on this topic in the literature
should be viewed cautiously because of their inherent
methodologic limitations. First, the small sample size and
lack of power often prevent an estimation of precise risk
estimates and do not allow exclusion of the potentially
increased risks linked to those medications.35 Second, the
lack of adjustment for either the level of asthma severity
and control, use of other asthma medications or known
teratogenic agents, maternal lifestyle characteristics (such
as cigarette smoking), or maternal medical conditions
during pregnancy (such as chronic hypertension or diabetes)
do not allow the reader to conclude if the reported effects
can be attributed to the medication under study or to
residual confounding.
Acknowledging the importance of increasing the body of
knowledge about the effects of asthma medications in
pregnancy and considering the aforementioned limitations,
the aim of the current review was to summarize the
evidence regarding the safety of ICSs during pregnancy and
on the neonate. To the best of our knowledge, this is the first
review of this topic to discuss the evidence presented in the
retained articles in light of power assessment.
Methods
Sources
Original studies published up to September 1, 2007, and
focusing mainly on the use of budesonide, beclomethasone
dipropionate, flunisolide, fluticasone propionate, and triam-cinolone acetonide to treat asthma during pregnancy were
researched in Pubmed and the Cochrane Library. The search
keywords were ICSs and the individual medications (bude-
sonide, beclomethasone dipropionate, flunisolide, flutica-
sone propionate, triamcinolone acetonide) in combination
with asthma and pregnancy. Reference lists of retained
articles were searched to identify pertinent articles. Only
articles written in English or French were retained.
Studies were included only if they provided information
on specific maternal and/or perinatal outcomes associated
with the use of ICSs during pregnancy. Maternal outcomes
included pregnancy-induced hypertension or preeclampsia,
caesarean section, hemorrhage (antepartum, postpartum,
and unspecified), gestational diabetes, and asthma exacer-
bations during pregnancy. Perinatal outcomes included
congenital malformations, preterm delivery, low birth
weight, stillbirth, perinatal mortality, and neonatal mortal-
ity. Studies were excluded if they did not report sufficient
information to allow calculation of the effect size. All
published studies included in this review were reviewed
independently by at least three of the authors.
The data collected from each study included the study
design, the type of ICSs studied, the definition of the control
group, the size of the ICS and control groups, the observed
proportions or means and standard deviations for the
selected outcomes in the ICS and control groups, the effect
size (crude or adjusted), and the p-value or 95% confidence
interval (CI) for the outcomes under study. A crude relative
risk (RR) or mean difference was calculated when the effect
size was not reported and sufficient information was
provided in the articles. Furthermore, we collected infor-
mation on the concurrent use of other asthma control
medications (long-acting beta2-agonists, theophyllines, and
leukotriene-receptor antagonists), systemic corticosteroids
(oral or intravenous), short-acting beta2-agonists (inhaled or
systemic), and intranasal corticosteroids.
Power calculations for the effect sizes observed in the
studies were performed for results that were not significant;
those were based on data reported in the published articles.
To provide a basis for comparisons among the different
studies addressing the same outcome, power to detect an RR
of 1.5 or a mean difference in the birth weight of 500 g also
was calculated. These power calculations were based on
t-tests for continuous outcomes and on the test for the
difference between two independent proportions for
dichotomous outcomes (Pass 2000 interface of NCSS soft-
ware). A type I error of 0.05 was used for power calculations
and a power of at least 80% was used as a cut-off for a study
to be considered to have sufficient power.Study selection
A total of 28 studies of the effects of ICSs on the selected
maternal and infant outcomes were retrieved from the
literature.6,10–34,36,37 Of those, we excluded five studies
because they provided insufficient information, leaving
23 studies for which the post hoc power could be
calculated.6,10–13,15–21,23,24,26,28–34,37 The excluded studies
were among the first to be published on this topic and were
mostly descriptive; they did not include a control group
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calculation.14,22,25,27,36
The 13 studies reporting associations between ICS use and
the selected maternal outcomes are shown in Table 1. They
include seven cohort studies,6,10,16,19–21,23 one nested case-
control study,12 one case-control study,13 three randomized
controlled trials (RCTs),11,15,17 and one study including both
a cohort study and an RCT.18 Six studies reported significant
results,13,15,16,19,20,23 and only one study did not provide
sufficient information to enable power calculation for some
outcomes.15
Nineteen studies investigated the association between
ICS use during pregnancy and perinatal outcomes,
including congenital malformations, preterm delivery,
low birth weight, and stillbirth and perinatal mortality
(Table 2).10,11,13,16–19,21,23,24,26,28–34,37 Fourteen were
cohort studies,10,16,19,21,23,24,26,28,30–34,37 two were case-
control studies,13,29 two were RCTs,11,17 and one was a
study including both a cohort and an RCT.18 Five studies
reported significant results.13,19,21,31,33 Power calculations
were performed for outcomes reported in 16 stu-
dies.10,11,13,16–19,21,23,24,26,28,31–34
Results
Maternal outcomes
Pregnancy-induced hypertension
Pregnancy-induced hypertension and gestational hyperten-
sion were the most frequently studied among the maternal
outcomes.11,12,15,16,18,21 No significant increases in the risk of
pregnancy-induced hypertension or gestational hypertension
were reported in the six studies that investigated this
outcome, with crude RRs ranging between 0.6 and
1.5.11,15,18,21 Two studies also provided adjusted RRs ranging
from 1.0 to 1.7.12,16 The power to detect the RRs observed in
the six studies ranged from 5% to 67%, whereas the power to
detect an RR of 1.5 varied from 7% to 92%, with only two
studies with a power of at least 80%.12,18 Three studies were
RCTs. In Wendel et al. and Silverman et al.,11,15 the small
sample sizes did not provide sufficient power to detect an RR
of 1.5; Schatz et al.18 had an 87% power to detect such an RR.
Preeclampsia
Preeclampsia was investigated in four studies and non-
significant associations were reported in all. Crude RR
estimates of preeclampsia ranged from 0.9 to 1.5,10,13,17
and one adjusted RR of 1.1 (95% CI, 0.7–1.5) was reported.12
The power for the RRs observed in the studies ranged from
5% to 25%, whereas the power to detect an RR of 1.5 varied
from 9% to 70%.
Caesarean section
Six studies investigated an association between use of ICSs
and the risk of caesarean section.11,13,15–17,19 Crude RR
estimates ranged from 1.0 to 3.2 and two studies reported
significant results.11,13,15,17,19 Perlow et al. obtained a crude
odds ratio of 3.0 (95% CI, 1.4–6.2) when comparing ICS users
with patients with no asthma and Norjavaara and de Verdier
obtained crude RRs of 1.2 (girls) and 1.3 (boys) (po0.05)
when comparing ICS users with women from the SwedishMedical Birth Registry, who delivered newborns of the
corresponding gender.13,19 One study reported adjusted RR
estimates ranging from 0.7 to 1.2 that were not signifi-
cant.16 For studies that did not provide significant results
and for which the power could be calculated, the power for
the RRs observed ranged from 5% to 58% and the power to
detect a RR of 1.5 varied from 9% to 46%.11,16,17
Hemorrhage
Two studies investigated the association between ICS use and
different subtypes of hemorrhages.16,17 Alexander et al.
reported that the risk of antepartum hemorrhage increased
among ICS users compared with patients without asthma
(aOR ¼ 2.2; 95% CI, 1.3–3.7), but this risk was non-significant
when comparisons were made with women with asthma who
did not use an ICS. For those non-significant results, the
power of this study was 17% when comparing those who did
not use an ICS and beta2-agonists and 29% when comparing
those who did not use an ICS who could have used beta2-
agonists, while the powers to detect a RR of 1.5 were,
respectively, 26% and 22%.16 Alexander et al.16 also reported
a significant 90% increase in the risk of postpartum
hemorrhage in those who used an ICS compared with those
who did not (not using any other asthma medication,
aOR ¼ 1.9 [1.3–2.7, 95% CI]). No significant increases in the
risk of postpartum hemorrhage were reported when compar-
ing women without asthma or non-users of ICSs, who could
also use beta2-agonists, with adjusted RRs of 1.5 and 1.7, and
powers ranging from 7% and 37% according to the control
group. The power to detect an RR of 1.5 also remained low,
ranging from 23% to 28%.16 Dombrowski et al.17 reported a
non-significant 20% increase in the risk of hemorrhage in their
RCT (95% CI, 0.5–2.6) but did not specify whether the
hemorrhage occurred antepartum or postpartum. This study
had only a 7% power to detect the observed RR and a 16%
power to detect an RR of 1.5.
Gestational diabetes
Three studies addressed the association between ICS use and
gestational diabetes.13,16,21 Reported crude RR estimates
ranged from 0.5 and 2.7, and Alexander et al. reported
adjusted ORs ranging from 0.9 to 2.5. No estimates of RR
were significant (power range, 11–39%), and the powers to
detect an RR of 1.5 ranged from 9% to 14%.13,16,21
Asthma exacerbations
The last maternal outcome of interest was asthma exacer-
bations during pregnancy, which was investigated in six
studies.6,15,17,20,21,23 The definition of asthma exacerbation
varied among studies. Stenius-Aarniala et al., Wendel et al.,
and Dombrowski et al. reported crude significant RR
estimates of 0.2 (95% CI, 0.1–0.4) and 0.3 (95% CI,
0.1–0.99), comparing those who used beclomethasone
dipropionate to those who did not use an ICS, and 2.4
(po0.05), comparing those who used beclomethasone
dipropionate to those who used triamcinolone aceto-
nide.15,20,23 Two studies by Dombrowski et al. compared
use of ICS to use of theophylline during pregnancy
and reported crude non-significant RR estimates of 0.9
(95% CI, 0.6–1.3), 1.2 (p40.05) and 2.8 (p-value unavail-
able).17,23 Schatz and Leibman compared users of ICSs
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Table 1 Study description and power calculations for selected maternal outcomes.
Study Design ICS users Control women Effect size
(precision: 95%
CI or p value)
Power (%)
for study
effect size
Power (%)
for
RR ¼ 1.5
ICS No. Outcome
(%)
Type of exposure No. Outcome
(%)
Outcomes
Pregnancy-induced hypertension (PIH)/gestational hypertension
Wendel et al.15 RCT BDPy,z,y 72 17.0 Authors’ obstetric
population
NA 13.0 cRR ¼ 1.3z J J
(NA)
Alexander et al.16 Cohort Anyy,z,y 105 18.1 Non-asthmatics 10 924 10.5 aOR ¼ 1.7 67 34
(1.0–2.9)
Anyy,z,y 105 18.1 Non-users of asthma
medications
292 13.7 aOR ¼ 1.3 21 29
(0.9–1.8)
Anyy,z,y 105 18.1 ICS non-usersy 234 11.1 aOR ¼ 1.0 43 24
(0.7–1.5)
Schatz et al.18 Cohort+
RCT
Anyy,z,y 722 11.2 ICS non-usersy 1401 11.7 cRR ¼ 1.0z 6 87
(p40.05)
Bakhireva et al.21 Cohort Anyy,y 438 3.0 Non-asthmatics 303 2.0 cRR ¼ 1.5z 13 12
(p40.05)
Anyy,y 438 3.0 ICS non-usersy 103 5.0 cRR ¼ 0.6z 21 11
(p40.05 )
Martel et al.12 Nested
case-
control
Anyy,z,y, 150 cases NA ICS non-usersy,z,y, 152 cases NA aRR ¼ 1.0 5 92
1403
controls
1610
controls
(0.8–1.3)
Silverman et al.11 RCT BUDy,z,y 102 1.0 Placebo usersy,z,y 117 1.7 cRR ¼ 0.6z 7 7
(NA)
Preeclampsia
Perlow et al.13 Cohortyy Anyy,z,y 50 2.0 Non-asthmatics 130 2.3 cOR ¼ 0.9 5 9
(0.4–9.5)
Schatz et al.10 Cohort Anyy,y 64 10.9 ICS non-usersy,y and non-
asthmatics
1197 7.1 cRR ¼ 1.5z 25 20
(NA)
Dombrowski et al.17 RCT BDPy 194 8.2 Theophylline usersy 190 7.9 cRR ¼ 1.0 5 21
(0.5–2.0)
Martel et al.12 Nested
case-
control
Anyy,z,y, 85 cases 10.6 ICS non-usersy,z,y, 80 cases 8.0 aRR ¼ 1.1 7 70
719
controls
924
controls
(0.7–1.5)
Caesarean section
Perlow et al.13 Cohortyy Anyy,z,y 50 56.0 Non-asthmatics 130 30.0 cOR ¼ 3.0
(1.4–6.2)
Wendel et al.15 RCT BDPy,z,y 72 30.0 Authors’ obstetric
population
NA 17.0 cRR ¼ 1.8z J J
(NA)
Alexander et al.16 Cohort Anyy,z,y 105 16.2 Non-asthmatics 10 959 19.6 aOR ¼ 0.7 12 46
(0.4–1.3)
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Table 1 (continued )
Study Design ICS users Control women Effect size
(precision: 95%
CI or p value)
Power (%)
for study
effect size
Power (%)
for
RR ¼ 1.5
ICS No. Outcome
(%)
Type of exposure No. Outcome
(%)
Anyy,z,y 105 16.2 Non-users of asthma
medications
293 22.5 aOR ¼ 1.2 26 37
(0.9–1.6)
Anyy,z,y 105 16.2 ICS non-usersy 234 22.2 aOR ¼ 1.2 23 34
(0.9–1.7)
Norjavaara et al.19 Cohort BUDy 1409 girls 13.1 Swedish medical birth
registry
143 017
girls
11.3 cRR ¼ 1.2z
(po0.05)
BUDy 1559 boys 16.2 Swedish medical birth
registry
150 931
boys
12.2 cRR ¼ 1.3z
(po0.001)
Dombrowski et al.17 RCT BDPy 194 15.5 Theophylline usersy 190 15.3 cRR ¼ 1.0 5 33
(0.6–1.6)
Silverman et al.11 RCT BUDy,z,y 102 10.8 Placebo usersy,z,y 117 3.4 cRR ¼ 3.2z 58 9
Antepartum hemorrhage (NA) (NA)
Alexander et al.16 Cohort Anyy,z,y 105 15.2 Non-asthmatics 1025 8.0 aOR ¼ 2.2
(1.3–3.7)
Anyy,z,y 105 15.2 Non-users of asthma
medications
276 11.6 aOR ¼ 1.4 17 26
(1.0–2.1)
Anyy,z,y 105 15.2 ICS non-usersy 230 10.0 aOR ¼ 1.2 29 22
(0.8–1.9)
Postpartum hemorrhage
Alexander et al.16 Cohort Anyy,z,y 84 14.3 Non-asthmatics 11 247 9.3 aOR ¼ 1.7 37 28
(1.0–3.2)
Anyy,z,y 84 14.3 Non-users of asthma
medications
235 15.3 aOR ¼ 1.9 5 26
(1.3–2.7)
Anyy,z,y 84 14.3 ICS non-usersy 202 12.9 aOR ¼ 1.5 7 23
(1.0–2.4)
Hemorrhage (unspecified)
Dombrowski et al.17 RCT BDPy 181 6.6 Theophylline usersy 177 5.6 cRR ¼ 1.2 7 16
(0.5–2.6)
Gestational diabetes
Perlow et al.13 Cohortyy Anyy,z,y 50 4.0 Non-asthmatics 130 1.5 cOR ¼ 2.7 23 9
(o0.1–212.7)
Alexander et al.16 Cohort Anyy,z,y 65 3.1 Non-asthmatics 10 267 1.5 aOR ¼ 2.5 39 13
(0.6–10.6)
Any y,z,y 65 3.1 Non-users of any asthma
medications
182 1.1 aOR ¼ 0.9 25 9
(0.2–3.5)
Anyy,z,y 65 3.1 ICS non-usersy 158 1.9 aOR ¼ 1.5 11 9
(0.5–4.8)
Bakhireva et al.21 Cohort Anyy,y 438 3.7 Non-asthmatics 303 2.3 cRR ¼ 1.6z 18 13
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(p40.05)
Anyy,y 438 3.7 ICS non-usersy 103 7.1 cRR ¼ 0.5z 36 14
(p40.05)
Maternal exacerbations
Dombrowski et al.23 Cohort BDPy,z 14 78.6 Theophylline usersz 25 28.0 cRR ¼ 2.8z 90 9
(NA)
TAAy,z 15 33.3 Theophylline usersz 25 28.0 cRR ¼ 1.2z 7 9
(p40.05)
BDPy,z 14 78.6 TAAy,z 15 33.3 cRR ¼ 2.4z
(po0.05)
Wendel et al.15 RCT BDPy,z,y 33 12.1 ICS non-usersz,y 27 33.3 cOR ¼ 0.3
(0.1–0.99)
(reversed in the
text)
Stenius-Aarniala
et al.20
Cohort Anyy,z,y, 257 3.9 ICS non-userszz,y,z,y, 177 17.5 cRR ¼ 0.2
(0.1–0.4)
Dombrowski et al.17 RCT BDPy 194 18.0 Theophylline usersy 191 20.4 cRR ¼ 0.9 9 39
(0.6–1.3)
Schatz et al.6 Cohort Anyy,y
Discontinued 53 41.5yy ICS non-usersy,y 483 29.6yy cRR ¼ 1.4z 43 29
(NA)
Continued 48 79.1yy ICS non-usersy,y 483 29.6yy cRR ¼ 2.7z 100 27
(NA)
Discontinued 53 5.7zz ICS non-usersy,y 483 3.1zz cRR ¼ 1.8z 23 13
(NA)
Continued 48 8.3zz ICS non-usersy,y 483 3.1zz cRR ¼ 2.7z 47 13
(NA)
Bakhireva et al.21 Cohort Anyy,y 438 1.6 ICS non-usersy 103 0.0 NA J J
Women participating in the different studies were asthmatic unless stated otherwise.
ICS: inhaled corticosteroids; BDP: beclomethasone dipropionate; TAA: triamcinolone acetonide; RCT: randomized controlled trial; BUD: budesonide; cOR: crude odds ratio; aOR: adjusted
odds ratio; cRR: crude relative risk; aRR: adjusted relative risk; cMD: crude mean difference; aMD: adjusted mean difference; NA: data not available.
Number of pregnancies unless stated otherwise.
yWomen may have concurrently received other asthma controller medications (long-acting beta2-agonists, theophylline, leukotriene-receptor antagonists, or cromolyn).
zWomen may have concurrently received systemic corticosteroids (oral or intravenous).
yWomen may have concurrently received short-acting beta2-agonists (inhaled or systemic).
zProportion or effect size was calculated based on information provided in the article.
JPower or effect size impossible to calculate.
Women may have concurrently received intra-nasal corticosteroids.
yyAuthors qualified the study design as a case-control but the data were presented as a cohort study.
zzExcept during one asthma exacerbation.
yyExacerbations defined as unscheduled medical visits.
zzExacerbations defined as emergency room visits.
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Table 2 Study description and power calculations for selected infant outcomes.
Study Design ICS users Control women Effect size
(precision: 95% CI
or p value)
Power (%)
for study’s
effect size
Power (%)
for
RR ¼ 1.5 or
MD ¼ 500 g
ICS No. Outcome
(% or
mean)
Type of exposure No. Outcome
(% or
mean)
Outcomes
Major malformations
Schatz et al.10 Cohort Anyy,z,y NA 5.4 ICS non-usersy,z and non-
asthmatics
NA 4.9 cRR ¼ 1.1z – –
(p40.05)
Kallen and Olausson29J Case-control Anyy,,z,y 7404 0.9 Swedish medical birth
registry
577 730 NA aOR ¼ 1.1 – –
(0.8–1.3)
Dombrowski et al.17 RCT BDPz 193 3.1 Theophylline usersz 189 2.6 cRR ¼ 1.2 6 11
(0.4–3.8)
Schatz et al.18 Cohort +
RCT
Anyy,,z 722 1.9 ICS non-usersy,,z 1401 2.0 cRR ¼ 1.0z 5 30
(p40.05)
Bakhireva et al.21 Cohort Anyy,z 438 4.1 Non-asthmatics 303 0.3 cRR ¼ 13.7z
(po0.05)
Anyy,z 438 4.1 ICS non-usersz 103 3.9 cRR ¼ 1.1z 5 9
(p40.05)
All malformations
Perlow et al.13 Cohortyy Anyy,,z 50 4.0 Non-asthmatics 130 2.3 cOR ¼ 1.3 13 9
(0.1–8.7)
Dombrowski et al.23 Cohort BDPy, 14 0 Theophylline users 25 0 – – –
(NA)
TAAy, 15 0 Theophylline users 25 0 – – –
(NA)
BDPy, 14 0 TAAy, 15 0 – – –
(NA)
Alexander et al.16 Cohort Anyy,,z 129 6.2 Non-asthmatics 12 740 7.7 aOR ¼ 0.8 7 33
(0.4–1.7)
Anyy,,z 129 6.2 Non-users of any asthma
medications
348 6.9 aOR ¼ 0.9 5 22
(0.6–1.4)
Anyy,,z 129 6.2 ICS non-usersz 282 8.5 aOR ¼ 1.0 11 23
(0.6–1.6)
Kallen et al.24 Cohort BUDz 2014 (b) 3.8 Swedish medical irth
registry
E300 000
(b)
3.5 cRR ¼ 1.1z 12 96
(NA)
Ericson and Kallen37 Cohort BUDy,z 2534 (b) 3.6 Swedish medical birth
registry
NA 3.6 cRR ¼ 1.0z – –
(NA)
Olesen et al.28 Cohort Anyy,,z 108 NA Non-users of any drugs 8717 NA – – –
(p40.05zz)
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Namazy et al.30 Cohort Any 394 (Lb) 1.0 US general population NA NA – –
(p40.05zz)
Silverman et al.11 RCT BUDy,,z 102 1.0 Placeboy,,z 117 3.4 cRR ¼ 0.3z 21 9
(NA)
Blais et al.31 Cohort Any
(mg/
day)y,,z,y
0–500 1582 9.0 ICS non-users 2740 9.4 aOR ¼ 0.8 7 98
(0.5–1.1)
501–1000 167 5.4 ICS non-users 2740 9.4 aOR ¼ 0.4
(0.2–0.9)
41000 72 12.5 ICS non-users 2740 9.4 aOR ¼ 1.0 18 25
(0.4–2.4)
Ka¨lle´n and Olausson26 Cohort Anyy,,z,y 12 478 5.0 ICS non-users 12 271 5.2 cRR ¼ 1.0z 11 100
(NA)
Mean birth weight
Dombrowski et al.23 Cohort BDPy, 14 2798.0 g Theophylline users 25 2984.0 g cMD ¼ 186.0 g 11 48
(p40.05)
TAAy, 15 3300.0 g Theophylline users 25 2984.0 g cMD ¼ 316.0 g 26 55
(p40.05)
BDPy, 14 2798.0 g TAAy, 15 3300.0 g cMD ¼ 502.0 g 47 46
(p40.05)
Olesen et al.28 Cohort Anyy,,z 108 3357.9 g Non-users of any drugs 8717 3414.0 g aMD ¼ 72.2 g 20 100
(179.2; 34.7)
Murphy et al.32 Cohort Any,z
(mg/day)
0–399 16 3635.0 g Non-asthmatics 25 3540.2 g cMD ¼ 94.8 g 7 65
(p40.05)
400–1500 32 3408.8 g Non-asthmatics 25 3540.2 g cMD ¼ 131.4 g 16 96
(p40.05)
41500 24 3355.0 g Non-asthmatics 25 3540.2 g cMD ¼ 185.2 g 20 86
(p40.05)
Murphy et al.33 Cohort Anyz 47 girls (b) 3375.5 g Non-asthmatics 15 girls (b) 3527.7 g aMD ¼ 152.2 g 23 98
(p40.05)
Anyz 43 boys (b) 3446.5 g Non-asthmatics 16 boys (b) 3601.9 g aMD ¼ 155.4 g 13 96
(p40.05)
Anyz 47 girls (b) 3375.5 g ICS non-usersz 22 girls (b) 3094.5 g aMD ¼ 281.0 g
(po0.05)
Anyz 43 boys (b) 3446.5 g ICS non-usersz 24 boys (b) 3701.5 g aMD ¼ 255.0 g 53 98
(p40.05)
Norjavaara and de
Verdier19
Cohort BUDz 1409 girls 3460.0 g Swedish medical birth
registry
143 017 girls 3500.0 g aMD ¼ 40.0 g
(po0.01)
BUDz 1559 boys 3610.0 g Swedish medical birth
registry
150 931 boys 3630.0 g aMD ¼ 20.0 g
(po0.001)
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Table 2 (continued )
Study Design ICS users Control women Effect size
(precision: 95% CI
or p value)
Power (%)
for study’s
effect size
Power (%)
for
RR ¼ 1.5 or
MD ¼ 500 g
ICS No. Outcome
(% or
mean)
Type of exposure No. Outcome
(% or
mean)
Dombrowski et al.17 RCT BDPz 194 3079.0 g Theophylline usersz 190 3063.0 g cMD ¼ 16.0 g 6 100
(p ¼ 0.97)
Namazy et al.30 Cohort BUD 43 (Lb) 3393.0 g Comparison made
between drugs
NA NA – – –
(p40.05zz)
BDP 201 (Lb) 3421.0 g NA NA – – –
(p40.05zz)
TAA 81 (Lb) 3508.0 g NA NA – – –
(p40.05zz)
Flu 132 (Lb) 3428.0 g NA NA – – –
(p40.05zz)
FP 25 (Lb) 3452.0 g NA NA – – –
(p40.05zz)
Bakhireva et al.21 Cohort Anyy,z 438 3524.0 g Non-asthmatics 303 3540.0 g 16.0 7 100
(p40.05yy)
Anyy,z 438 3524.0 g ICS non-usersz 103 3552.0 g 28.0 8 100
(p40.05yy)
Low birth weight o2500 g
Perlow et al.13 Cohortyy Anyy,,z 50 14.0 Non-asthmatics 130 4.6 cOR ¼ 3.4 57 11
(0.9–12.1)
Schatz et al.10 Cohort Anyy,z 64 4.7 ICS non-usersy,z and non-
asthmatics
1197 3.3 cRR ¼ 1.4z 14 15
(NA)
Alexander et al.16 Cohort Anyy,,z 98 5.1 Non-asthmatics 10 607 5.6 aOR ¼ 1.0 5 24
(0.4–2.5)
Anyy,,z 98 5.1 Non-users of asthma
medications
286 4.9 aOR ¼ 0.9 5 16
(0.5–1.5)
Anyy,,z 98 5.1 ICS non-usersz 228 7.9 aOR ¼ 1.4 13 19
(0.8–2.2)
Namazy et al.30 Cohort Any 396 (Lb) 3.3 USA general population NA NA – –
(p40.05zz)
Schatz et al.18 Cohort+RCT Anyy,,z 722 13.0 ICS non-usersy,,z 1401 14.1 cRR ¼ 0.9z 10 91
(p40.05)
Low birth weight o1000 g
Perlow et al.13 Cohortyy Anyy,,z 50 4.0 Non-asthmatics 130 0.8 cOR ¼ 5.3 37 8
(0.1–241.0)
Norjavaara and de
Verdier19
Cohort BUDz 1409 girls 0.3 Swedish medical birth
registry
143 017 girls 0.1 cRR ¼ 3.0z 59 15
(p40.05)
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BUDz 1559 boys 0.1 Swedish medical birth
registry
150 931 boys 0.1 cRR ¼ 1.0z 5 15
(p40.05)
Preterm delivery o37 weeks
Perlow et al.13 Cohortyy Anyy,,z 50 14.0 Non-asthmatics 130 3.9 cOR ¼ 4.0
(1.1–15.5)
Schatz et al.10 Cohort Anyy,z 64 7.8 ICS non-usersy,z
asthmatic or not
1195 3.8 cRR ¼ 2.1z 40 16
(NA)
Alexander et al.16 Cohort Anyy,,z 91 7.7 Non-asthmatics 9017 6.0 aOR ¼ 1.4 14 24
(0.6–3.0)
Anyy,,z 91 7.7 Non-users of asthma
medications
214 5.6 aOR ¼ 1.0 12 15
(0.5–1.7)
Anyy,,z 91 7.7 ICS non-usersz 183 6.0 aOR ¼ 1.0 9 15
(0.5–1.8)
Bracken et al.34 Cohort Anyy,,z 176 8.5 ICS non-users asthmatic
or noty,,z
2029 6.7 aOR ¼ 0.99zz 17 35
(0.98–1.01)
Dombrowski et al.17 RCT BDPz 194 20.6 Theophylline usersz 190 16.3 cRR ¼ 1.3 19 34
(0.8–1.9)
Namazy et al.30 Cohort Any 396 (Lb) 6.1 US general population NA NA – –
(p40.05zz)
Schatz et al.18 Cohort +
RCT
Anyy,,z 722 16.2 ICS non-usersy,,z 1401 16.4 cRR ¼ 1.0z 5 94
(p40.05)
Bakhireva et al.21 Cohort Anyy,z 438 6.6 Non-asthmatics 303 7.6 cRR ¼ 0.9z 8 33
(p40.05)
Anyy,z 438 6.6 ICS non-usersz 103 11.7 cRR ¼ 0.6z 43 21
(p40.05)
Preterm delivery o32 weeks
Perlow et al.13 Cohortyy Anyy,,z 50 5.9 Non-asthmatics 130 1.6 cOR ¼ 4.1 38 9
(0.5–47.4)
Schatz et al.18 Cohort+RCT Anyy,,z 722 3.2 ICS non-usersy,,z 1401 3.4 cRR ¼ 0.9z 5 44
(p40.05)
Stillbirth
Norjavaara and de
Verdier19
Cohort BUDz 1409 girls 0.3 Swedish medical birth
registry
143 017 girls 0.3 cRR ¼ 1.0 5 23
(p40.05)
BUDz 1559 boys 0.1 Swedish medical birth
registry
150 931 boys 0.3 cRR ¼ 0.3 19 24
(p40.05)
Perinatal death
Dombrowski et al.17 RCT BDPz 184 1.5 Theophylline usersz 190 2.1 cRR ¼ 0.7 7 10
(0.2–3.2)
Women participating in the different studies were asthmatic unless stated otherwise.
ICS: inhaled corticosteroids; BDP: beclomethasone dipropionate; TAA: triamcinolone acetonide; RCT: randomized controlled trial; BUD: budesonide; aOR: adjusted odds ratio; cOR: crude
odds ratio; cRR: crude risk ratio; cMD: crude mean difference; aMD: adjusted mean difference; mg: micrograms; b: births; Lb: live births; NA: data unavailable; –: power or effect size
impossible to calculate.
Number of pregnancies unless stated otherwise.
yWomen may have concurrently received asthma controller medications (long-acting beta2-agonists, theophylline, leukotriene modifiers) or cromolyn.
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zWomen may have concurrently received short-acting beta2-agonists (inhaled or systemic).
yWomen may have concurrently received intranasal corticosteroids.
zEffect size was calculated based on information provided in the articles.
JCardiovascular malformations only.
Women may have concurrently received systemic corticosteroids (oral or intravenous).
yyAuthors qualified the study design as a case-control but the data was presented as a cohort study.
zzp values associated with crude models.
yyp values associated with adjusted models.
zzRisk associated for each additional mg of ICS.
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non-users of ICSs and reported the rates of asthma
exacerbations, which allowed for the calculation of RR
estimates ranging between 1.4 and 2.7.6 Bakhireva et al. did
not report an effect size for asthma exacerbations because
none of the subjects who did not use ICS had an asthma
exacerbation.21 For the studies reporting non-significant
results or for which the p-value was unknown, the power for
the observed RRs ranged from 7% to 100% and for an RR of
1.5, from 9% to 39%.6,17,23Infant outcomes
Congenital malformation
Fifteen studies investigated the risk of congenital mal-
formations associated with the use of ICSs during preg-
nancy.10,11,13,16–18,21,23,24,26,28–31,37 The crude and adjusted
RR estimates ranged from 0.3 to 13.7 and from 0.4 to 1.1,
respectively. Bakhireva et al.21 were the only authors to
report a significantly increased risk of congenital malforma-
tions associated with ICS use, when they compared 438
pregnant women using ICSs during pregnancy with 303
women without asthma (cRR ¼ 13.7, po0.05). Only one
study investigated the ICS dose in greater details and
reported a significant protective effect of ICSs on the risk of
congenital malformations, at daily doses ranging from 501 to
1000mcg of beclometasone-CFC equivalent (aOR ¼ 0.4; 95%
CI [0.2–0.9]) when ICS users were compared to women with
asthma not using ICSs during pregnancy.31 The studies had
powers ranging from 9% to 100% to detect an RR of 1.5, with
only three studies having at least an 80% power to detect
this RR estimate.24,26,31Mean birth weight
Eight studies evaluated the association between the
mean birth weight and ICS use during preg-
nancy.17,19,21,23,28,30,32,33 Depending on the control group,
crude and adjusted mean birth weight differences ranged
from 502.0 to 316.0 g and from 255.0 and 281.0 g,
respectively. Significant associations between ICS use during
pregnancy and mean birth weight were found in two cohort
studies.19,33 In a study by Murphy et al.33 that included 47
female newborns and 43 male newborns exposed to ICSs
during pregnancy, an increased mean birth weight in female
newborns was observed compared with the babies of
asthmatic women who did not use an ICS (mean difference,
281 g, po0.05), but no significant difference was observed
compared with the babies of women without asthma.
Moreover, no significant change in the mean birth weight
was observed among male newborns. Norjavaara and de
Verdier reported a significant effect of ICS use on the mean
birth weight among 1409 girls and 1559 boys compared to all
girls (n ¼ 143 017) and boys (n ¼ 150 931) born in Sweden
between 1995 and 1998 (boys, 20 g, po0.001; girls, 40 g,
po0.01).19 Among studies providing non-significant results,
the power to detect the observed mean birth weight
difference ranged from 6% to 47%21,28,32,33; five studies
had more than an 80% power to detect a mean difference of
at least 500 g.17,21,28,32,33Low birth weight
Six studies investigated the association between low birth
weight (o2500 and o1000 g) and ICS use during preg-
nancy.10,13,16,18,19,30 Crude RR estimates ranged from 0.9 to
5.310,13,18,19,30 and one study reported adjusted RR esti-
mates ranging from 0.9 to 1.4.16 However, no studies
reported significant associations between ICS use during
pregnancy and low birth weight. All studies had a power
lower than 80% to detect the observed RRs (range 5–59%).
Only Schatz et al. reported a power greater than 80% to
detect an RR of 1.5,18 and all other studies had powers
ranging from 8% to 24% to detect such an RR esti-
mate.10,13,16,19,30
Preterm delivery
Eight studies focused on the effect of ICS use during
pregnancy on preterm delivery (o37 weeks and o32
weeks).10,13,16–18,21,30,34 The crude and adjusted RR esti-
mates ranged from 0.6 and 4.0 and between 0.99 and 1.4,
respectively. Only Perlow et al. reported a significant
association between the risk of preterm delivery and ICS
use during pregnancy.13 Preterm delivery occurred signifi-
cantly more often in women who used an ICS compared with
women without asthma (cOR ¼ 4.0; 95% IC, 1.1–15.5). All
other studies had a power below 80% to detect the observed
RR, ranging from 5% to 43%. Only Schatz et al. had sufficient
power (94%) to detect an RR of 1.5,18 while all other studies
had powers ranging from 9% to 44% to detect such an RR
estimate.10,13,16,17,21,30,34
Stillbirth, perinatal mortality, and neonatal mortality
No study met our criteria for the neonatal mortality
outcome. Two studies investigated stillbirth and perinatal
mortality, and no significant increased risk among pregnant
women using ICSs was observed.17,19 No study had a power
greater than 80% to detect the observed RR (range 5–19%)
and had sufficient power to detect an RR of 1.5 (range
10–24%).
Discussion
The current review focused on 23 studies investigating
maternal and/or perinatal outcomes in association with ICS
use during pregnancy.6,10–13,15–21,23,24,26,28–34,37 Based on
this review, we concluded that ICSs can significantly reduce
the risk of asthma-related readmissions during pregnancy
when used after hospital discharge15 and significantly
reduce the risk of asthma exacerbations when used during
pregnancy.15,20,23 In addition, a significant increase in the
mean birth weight was found in female newborns of women
with asthma taking ICSs compared to female newborns of
women with asthma not taking ICSs during pregnancy.33
However, in some studies, pregnant women with asthma
using ICSs were at increased risk of caesarean section,13,19
antepartum hemorrhage,16 preterm delivery,13 and having a
baby with a congenital malformation,21 compared with
women without asthma. Further, a significant reduction in
the mean birth weight was observed in newborns of women
with asthma taking ICSs compared with the general
population.19 However, no significant associations were
reported when pregnant women with asthma taking ICSs
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ICSs in relation to all outcomes under study, except for the
mean birth weight, which was significantly higher for female
newborns exposed to ICSs.33 It should be noted that the most
extensive safety information is provided for budesonide19
and that no study focused exclusively on the other ICSs.
The reported negative results should be interpreted with
caution since several studies had low power. A non-
significant association could produce a misleading impres-
sion of safety and lead to false conclusions regarding the
safety of ICSs during pregnancy. Among studies investigating
dichotomous outcomes, only nine of the 23 studies reviewed
had a power of 80% or more to detect the observed RR for at
least one outcome investigated.6,13,15,16,19–21,23,31 Among
studies providing non-significant results, only six studies had
a power of 80% or more to detect an RR estimate of 1.5 for
at least one outcome investigated.12,17,18,21,24,31 We chose
an RR estimate of 1.5 for power calculation and comparison
among studies, because we considered that a 50% increase
in the risk of the outcomes studied would be clinically
relevant while remaining realistic, with awareness that most
outcomes are (from a statistical standpoint) rare events.
Among the eight studies investigating the mean birth
weight (continuous outcome), two studies had a power of
80% or more to detect the observed mean difference.19,33
Among studies providing non-significant results, five studies
had a power of 80% or more to detect a mean difference of
500 g.17,21,28,32,33 We chose a mean birth weight difference
of 500 g for power calculations and comparison among
studies, because it might be considered a clinically relevant
reduction in birth weight in most cases. Moreover, subtract-
ing 500 g from the Canadian average birth weight would
bring it close to the standard low birth weight limit
(o2500 g).38
We also observed that reported RR estimates varied
considerably among studies investigating the same out-
comes. Apart from the variability that might arise from
small samples sizes, extra variability in several studies also
might arise from the reporting of crude results that provide
estimates that can be confounded. Indeed, asthma control
and severity may act as important confounders since they
can be associated with the use of ICSs and are associated
with adverse perinatal outcomes.43 Women using ICSs,
especially those starting treatment during pregnancy, are
likely to have uncontrolled or severe asthma, which might
contribute to the underestimation of the beneficial effects
of ICSs on perinatal outcomes. In addition, the use of
different control groups between studies, i.e., pregnant
women without asthma, women with asthma not using ICSs
during pregnancy, and women with asthma using theophyl-
lines during pregnancy, might have contributed to the
variability of the results. The current review identified only
nine studies with a control group of women with asthma not
using ICSs during pregnancy, which could be considered the
most appropriate control group to investigate the effects of
ICSs during pregnancy.12,15,16,18,20,21,26,31,33 Using this type
of control group makes the compared groups more similar in
terms of maternal health, but despite that, it is essential to
adjust for the level of severity and asthma control, because
they are likely to vary between users and non-users of ICSs
and thus, confound the results. Only a few studies had RRs
adjusted for asthma severity and control; use of otherasthma medications, especially oral corticosteroids; or for
other potential confounders, and this also may have
contributed to the variability of the results.12,31,34
In their publications, some authors acknowledged the
difficulties associated with the lack of power and provided
the reader with useful information about power calcula-
tions.10,16,18,19 Further, some recent review articles on the
safety of asthma medications during pregnancy35,39–43 also
acknowledged the power limitations of several stu-
dies.35,39,42,43 However, it is important to recognize that
small sample sizes in studies could be due to the difficulty
recruiting pregnant women with asthma and that the lack of
adjustment could be due to the complexity in obtaining
suitable information about potential confounding vari-
ables.35 A meta-analysis was done on the safety of the use
of ICSs in pregnancy, but only four studies were included as a
result of the heterogeneity of the studies retrieved in the
literature.44
It is important to determine precisely the risks and
benefits of asthma medications during pregnancy, since
women with asthma and their treating physicians need to
identify the best treatment regimens that will allow them to
control asthma while minimizing the risks to the fetus.
There is some degree of scientific evidence on the effects of
ICS use during pregnancy; current guidelines recommend use
of ICSs during pregnancy, because they could provide more
benefit to women than no treatment. Still, several out-
comes, such as pregnancy-induced hypertension, pree-
clampsia, caesarean section, hemorrhage, gestational
diabetes, low birth weight, stillbirth, perinatal death, and
neonatal death need further investigation before definitive
conclusions can be reached about the safety of ICS use
during pregnancy. Future studies conducted in this field will
increase the knowledge base, especially if they can address
the power and methodologic issues raised in the current
review.
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